Mikkael A Sekeres
Mikkael A Sekeres
Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historica...
Elias Jabbour,Francis J Giles
Elias Jabbour
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myeloid leukemia (AML). Therapeut...
E J Feldman
E J Feldman
The farnesyltransferase inhibitors (FTIs) are in active clinical development in a variety of human malignancies. The most promising activity to date has been demonstrated in patients with hematologic malignancies, in particular acute myeloi...
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good? [0.03%]
来那度胺(瑞复美，CC-5013)治疗骨髓增生异常综合征：疗效如何？
Mikkael A Sekeres,Alan List
Mikkael A Sekeres
The myelodysplastic syndromes (MDS) can be divided into "early" and "advanced" disease by evaluation of prognostic variables such as the number of cytopenias, karyotype, and percentage of myeloblasts. Patients with an isolated interstitial ...
Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification [0.03%]
WHO在骨髓增生异常综合征中的临床意义是什么？
Rami S Komrokji,John M Bennett
Rami S Komrokji
Myelodysplastic syndromes (MDS) are a heterogeneous group of neoplastic clonal stem cell diseases characterized by dysplastic morphologic features with a varying percentage of leukemic blasts and clinical bone marrow failure. The French-Ame...
Novel approaches to the immunotherapy of B-cell malignancies: An update [0.03%]
B细胞恶性肿瘤免疫治疗的新方法：最新研究进展
Renier J Brentjens
Renier J Brentjens
Immunotherapy of cancer includes both active and adoptive, or passive, forms of immunization to target and eradicate malignant B cells in the host. Advances in the understanding of immunology and tumor-cell evasion of the host immune system...
Stefan Faderl,William Wierda,Michael J Keating
Stefan Faderl
Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as...
John W Sweetenham
John W Sweetenham
Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease. These studies have demonstrated leuke...
Treatment of Burkitt lymphoma in children and adults: Lessons from Africa [0.03%]
儿童及成人 Burkitt 淋巴瘤的治疗——来自非洲的经验教训
Ian T Magrath
Ian T Magrath
Modern chemotherapy for childhood Burkitt lymphoma has its origins in Africa, where treatment evolved from one or two doses of single agents, which were curative in some patients, to combinations of non-cross-resistant drugs. Subsequently, ...
The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma [0.03%]
利妥昔单抗在自身和同种异体造血干细胞移植治疗非霍奇金淋巴瘤中的作用
Elizabeth Naparstek
Elizabeth Naparstek
The addition of rituximab to chemotherapy has substantially changed the treatment strategies for patients with B-cell lymphomas. Rituximab, combined with standard chemotherapy regimens, shows consistently improved results compared with chem...